email query to obj, re ann's, page-21

Some detail from 18/2/2010 ann said:

OBJ first collaborated with GSK in 2006 in an advanced delivery program employing the Company??s Dermaportation technology. This program was further expanded to involve
both the Company??s Dermaportation and ETP technologies. This relationship was announced to shareholders in May 2007 following approval of that release by GSK. A
further confidential collaboration with GSK was undertaken in 2008 in an undisclosed consumer healthcare field and the current announcement continues the work in that
same commercial field. The results, application field and drug used in the current program are, by agreement,
to remain confidential.

Which means they are working closely and by agreement to remain confidential. Therefore in the current ann, they say not material because if OBJ say something, OBJ will break the agreement and may harmful to both party.

Maybe an ann will soon be released if they make some progress on the agreement. As they mentioned GSK is evaluate it, so further ann maybe come soon IMO

cheers